A new medication called IZERVAY has demonstrated significant benefits for people with geographic atrophy, a progressive eye disease that causes central vision loss. In pooled analysis of two major clinical trials, the drug reduced the risk of progressing to loss of driving eligibility by 41% compared to a placebo over 24 months, with only 12.6% of IZERVAY-treated patients losing driving eligibility versus 20.1% in the control group.

What Is Geographic Atrophy and Why Does It Matter?

Geographic atrophy (GA) is a form of age-related macular degeneration (AMD), a condition affecting the macula, the part of the retina responsible for sharp central vision. Unlike wet AMD, which develops suddenly, geographic atrophy progresses gradually, causing a slow expansion of dead cells in the retina. This progressive vision loss can make everyday activities like reading, recognizing faces, and driving increasingly difficult. For many people, maintaining the ability to drive represents independence and quality of life, making IZERVAY's impact on driving eligibility particularly meaningful.

How Does IZERVAY Work and What Do the Studies Show?

IZERVAY (avacincaptad pegol) is a complement therapy, meaning it targets a specific part of the immune system that contributes to retinal damage in geographic atrophy. The drug is administered as a monthly injection directly into the eye. Beyond the driving eligibility findings, long-term data from an open-label extension study presented at the American Academy of Ophthalmology conference in 2025 demonstrated that IZERVAY continued to reduce geographic atrophy lesion growth for up to 3.5 years with ongoing monthly treatment.

Notably, earlier intervention with IZERVAY resulted in greater protection of retinal tissue. In the extension study, disease progression was reduced by 37% to 40.5% compared to projected outcomes without treatment, suggesting that starting therapy sooner may offer better long-term outcomes.

What About Safety and Long-Term Use?

Safety has been a consistent strength of IZERVAY across clinical trials. The medication was well-tolerated with no new safety signals emerging through 3.5 years of treatment. Importantly, there were no cases of retinal vasculitis (inflammation of blood vessels in the retina) or occlusive vasculitis, and no increased risk of intraocular inflammation, concerns that sometimes accompany eye treatments. In February 2025, the FDA approved an expanded label for IZERVAY without limitation on duration of dosing, providing greater flexibility for long-term management of geographic atrophy.

How Is IZERVAY Being Adopted in Clinical Practice?

Since receiving a permanent billing code in April 2024, IZERVAY has seen steady uptake. More than 210,000 vials were distributed in the United States through December 2024, with month-over-month growth continuing since that time. This adoption reflects growing recognition among ophthalmologists of the drug's benefits for preserving vision and maintaining functional independence in patients with geographic atrophy.

Steps for Identifying Candidates for Complement Therapy

• Early Detection: Patients with diagnosed geographic atrophy or intermediate age-related macular degeneration should discuss complement therapy options with their eye care provider, as earlier intervention appears to offer greater protection of retinal tissue.
• Comprehensive Eye Examination: A thorough ophthalmologic evaluation, including imaging of the retina, is necessary to confirm geographic atrophy and assess disease stage and progression rate.
• Functional Assessment: Doctors should evaluate how the disease is affecting daily activities, including driving ability, to help determine whether IZERVAY treatment aligns with the patient's priorities and lifestyle.
• Discussion of Expectations: Patients should understand that IZERVAY slows progression rather than restoring lost vision, and that monthly injections are required for sustained benefit.

"Earlier intervention with IZERVAY resulted in greater protection of retinal tissue area, with disease progression reduced 37% to 40.5% versus projected sham in the extension study," noted Rishi P. Singh, MD, FASRS, Chair of the Department of Ophthalmology at Mass General Brigham.

Rishi P. Singh, MD, FASRS, Chair of the Department of Ophthalmology at Mass General Brigham

What Does This Mean for Patients and Eye Care?

The approval and growing adoption of IZERVAY represent a meaningful advance for the estimated millions of people living with geographic atrophy worldwide. For decades, this condition had no disease-modifying treatment options, leaving patients to watch their vision decline without medical intervention. The ability to slow progression and preserve driving eligibility addresses one of the most important functional concerns for people with this disease. As more ophthalmologists become familiar with patient selection criteria and treatment protocols, access to this therapy is expected to expand, offering hope to people facing vision loss from this previously untreatable condition.